Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly Noonan

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Molecular Cancer Therapeutics|August 29, 2012
Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapyAtul Bedi, Xiaofei Chang, Kimberly Noonan, et al.
Expert Review of Hematology|January 26, 2012
Management of myeloma-associated renal dysfunction in the era of novel therapiesMahmoud R Gaballa, Jacob P Laubach, Robert L Schlossman, et al.
Oncology (Williston Park, N.Y.)|June 4, 2010
Tailoring treatment for multiple myeloma patients with relapsed and refractory diseasePaul G Richardson, Jacob Laubach, Constantine Mitsiades, et al.
Leukemia Research|December 5, 2003
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivoJonathan W Friedberg, Danielle A Dong, Sigui Li, et al.
European Journal of Haematology|February 4, 2012
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomibPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2020
Antiemetics: ASCO Guideline UpdatePaul J Hesketh, Mark G Kris, Ethan Basch, et al.
Journal of Translational Medicine|July 12, 2017
Impaired B cell immunity in acute myeloid leukemia patients after chemotherapyMeghali Goswami, Gabrielle Prince, Angelique Biancotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2017
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdatePaul J Hesketh, Mark G Kris, Ethan Basch, et al.
American Journal of Hematology|August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myelomaIrene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Molecular Cancer Therapeutics|August 29, 2012
Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapyAtul Bedi, Xiaofei Chang, Kimberly Noonan, et al.
Expert Review of Hematology|January 26, 2012
Management of myeloma-associated renal dysfunction in the era of novel therapiesMahmoud R Gaballa, Jacob P Laubach, Robert L Schlossman, et al.
Oncology (Williston Park, N.Y.)|June 4, 2010
Tailoring treatment for multiple myeloma patients with relapsed and refractory diseasePaul G Richardson, Jacob Laubach, Constantine Mitsiades, et al.
Leukemia Research|December 5, 2003
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivoJonathan W Friedberg, Danielle A Dong, Sigui Li, et al.
European Journal of Haematology|February 4, 2012
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomibPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2020
Antiemetics: ASCO Guideline UpdatePaul J Hesketh, Mark G Kris, Ethan Basch, et al.
Journal of Translational Medicine|July 12, 2017
Impaired B cell immunity in acute myeloid leukemia patients after chemotherapyMeghali Goswami, Gabrielle Prince, Angelique Biancotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2017
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdatePaul J Hesketh, Mark G Kris, Ethan Basch, et al.
American Journal of Hematology|August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myelomaIrene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.
Pageof 3